Apellis will receive an upfront payment of $250m from Sobi. Credit: 漏 Swedish Orphan Biovitrum AB.

has entered into a Biovitrum (Sobi) to fast-track the advancement of systemic pegcetacoplan to treat multiple rare diseases with high unmet need.

Apellis will receive an upfront payment of $250m from Sobi and is eligible to get up to $915m as milestone payments, along with tiered double-digit royalties on sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the deal, Sobi will also provide $80m in reimbursement payments over four years for research and development to support the initial development plan.

and CEO Cedric Francois said: 鈥淭his collaboration enables us to further expand on the broad platform potential of targeting C3 for serious rare diseases that impact hundreds of thousands of patients around the world.

鈥淭ogether, we will quickly advance systemic pegcetacoplan in multiple registrational programmes across haematology, nephrology, and neurology while also preparing for our first potential US launch in PNH.鈥�

Pegcetacoplan targets excessive activation of C3 in the complement cascade, part of the immune system, which can aid in progression of serious ailments.

Together, the companies will advance systemic pegcetacoplan in five parallel registrational programmes including two new haematological studies, CAD and HSCT-TMA, set to start next year.

These include ongoing programmes in haematology (PNH), nephrology (IC-MPGN/C3G) and neurology (ALS).

According to the deal, Sobi will get global co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan.

Apellis will retain US commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, which is in Phase III trials for geographic atrophy (GA).

Apellis will take care of all regulatory and commercial activities in the US and the ongoing marketing authorisation application (MAA) review for PNH in the European Union, which will be later transferred to Sobi.

Sobi will handle all regulatory and commercial activities for systemic pegcetacoplan in ex-US markets.

In April, Sobi released the 2020 Haemophilia Index, a report that analyses the quality of life of patients treated for haemophilia in聽Europe.